376638-65-2 Usage
General Description
"BVT-14225" is a chemical compound that belongs to the class of phosphodiesterase inhibitors. It has been studied for its potential use in the treatment of a variety of conditions, including asthma, chronic obstructive pulmonary disease (COPD), and other respiratory diseases. BVT-14225 has shown promising results in preclinical studies, demonstrating the ability to relax smooth muscle cells in the airways and improve lung function. Its mechanism of action involves inhibiting the breakdown of cyclic adenosine monophosphate (cAMP), leading to relaxation of the smooth muscle in the airways. Additionally, BVT-14225 has been shown to have anti-inflammatory properties, suggesting potential use in reducing airway inflammation in respiratory conditions. Further research and clinical trials are needed to fully understand the efficacy and safety of BVT-14225 for medical use.
Check Digit Verification of cas no
The CAS Registry Mumber 376638-65-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,7,6,6,3 and 8 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 376638-65:
(8*3)+(7*7)+(6*6)+(5*6)+(4*3)+(3*8)+(2*6)+(1*5)=192
192 % 10 = 2
So 376638-65-2 is a valid CAS Registry Number.
376638-65-2Relevant articles and documents
Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1
Barf, Tjeerd,Vallg?rda, Jerk,Emond, Rikard,H?ggstr?m, Charlotta,Kurz, Guido,Nygren, Alf,Larwood, Vivienne,Mosialou, Erifili,Axelsson, Kent,Olsson, Rolf,Engblom, Lars,Edling, Naimie,R?nquist-Nii, Yuko,?hman, Birgitta,Alberts, Peteris,Abrahmsén, Lars
, p. 3813 - 3815 (2007/10/03)
Novel antidiabetic arylsulfonamidothiazoles are presented that exert action through selective inhibition of the 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme, thereby attenuating hepatic gluconeogenesis. The diethylamide derivative 2a was shown to potently inhibit human 11β-HSD1 (IC50 = 52 nM), whereas the N-methylpiperazinamide analogue 2b only inhibited murine 11β-HSD1 (IC50 = 96 nM). Both compounds showed >200-fold selectivity over human and murine 11β-HSD2. 2b was subsequently shown to reduce glucose levels in diabetic KKAy mice, substantiating the 11β-HSD1 enzyme as a target for the treatment of type 2 diabetes.
